

# ElÅ¼bieta Wyska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4692740/publications.pdf>

Version: 2024-02-01

90  
papers

1,806  
citations

304743  
22  
h-index

330143  
37  
g-index

93  
all docs

93  
docs citations

93  
times ranked

2286  
citing authors

#	ARTICLE	IF	CITATIONS
1	<b>PK/PD Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis</b>. Journal of Pharmacology and Experimental Therapeutics, 2022, , JPET-AR-2021-001004.	2.5	2
2	Pan-Phosphodiesterase Inhibitors Attenuate TGF- $\beta$ <sup>2</sup> -Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals, 2022, 15, 423.	3.8	4
3	Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases. Pharmaceutics, 2022, 14, 1090.	4.5	1
4	New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. European Journal of Medicinal Chemistry, 2021, 209, 112854.	5.5	16
5	Effects of classic antiseizure drugs on seizure activity and anxiety-like behavior in adult zebrafish. Toxicology and Applied Pharmacology, 2021, 415, 115429.	2.8	12
6	PK/PD Modeling of the PDE7 Inhibitor “GRMS-55 in a Mouse Model of Autoimmune Hepatitis. Pharmaceutics, 2021, 13, 597.	4.5	4
7	Anticonvulsant effect of pterostilbene and its influence on the anxiety- and depression-like behavior in the pentetrazol-kindled mice: behavioral, biochemical, and molecular studies. Psychopharmacology, 2021, 238, 3167-3181.	3.1	15
8	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. Journal of Medicinal Chemistry, 2021, 64, 12603-12629.	6.4	5
9	Effect of Ellagic Acid on Seizure Threshold in Two Acute Seizure Tests in Mice. Molecules, 2021, 26, 4841.	3.8	3
10	A new class of 5-HT <sub>1A</sub> receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	2.3	2
11	Effects of new antiseizure drugs on seizure activity and anxiety-like behavior in adult zebrafish. Toxicology and Applied Pharmacology, 2021, 427, 115655.	2.8	9
12	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer’s Disease. Current Medicinal Chemistry, 2021, 28, 6082-6094.	2.4	2
13	Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. Bioorganic Chemistry, 2021, 117, 105409.	4.1	11
14	Identification of New Compounds with Anticonvulsant and Antinociceptive Properties in a Group of 3-substituted (2,5-dioxo-pyrrolidin-1-yl)(phenyl)-Acetamides. International Journal of Molecular Sciences, 2021, 22, 13092.	4.1	5
15	Ligands of the CB <sub>2</sub> cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice. Behavioural Brain Research, 2020, 378, 112297.	2.2	10
16	Comparative Assessment of the New PDE7 Inhibitor “GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach. Pharmaceutical Research, 2020, 37, 19.	3.5	12
17	Influence of the CB <sub>1</sub> and CB <sub>2</sub> cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice. Pharmacology Biochemistry and Behavior, 2020, 188, 172833.	2.9	11
18	Discovery of Novel pERK1/2- or $\beta$ <sup>2</sup> -Arrestin-Preferring 5-HT <sub>1A</sub> Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. Journal of Medicinal Chemistry, 2020, 63, 10946-10971.	6.4	15

#	ARTICLE	IF	CITATIONS
19	Novel anilide and benzamide derivatives of arylpiperazinylalkanoic acids as 5-HT <sub>1A</sub> /5-HT <sub>7</sub> receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	5.5	19
20	A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF- $\beta$ <sup>2</sup> Signaling and Activation of cAMP/PKA Signaling. International Journal of Molecular Sciences, 2020, 21, 4008.	4.1	28
21	Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice. Pharmacological Reports, 2020, 72, 1562-1572.	3.3	8
22	KM-416, a novel phenoxyalkylaminoalkanol derivative with anticonvulsant properties exerts analgesic, local anesthetic, and antidepressant-like activities. Pharmacodynamic, pharmacokinetic, and forced degradation studies. European Journal of Pharmacology, 2020, 886, 173540.	3.5	5
23	Late Breaking Abstract - Anti-inflammatory and anti-fibrotic effect of novel, pan-PDE inhibitors in human bronchial epithelial cells. , 2020, , .		0
24	Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6â€ Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. Neuropharmacology, 2019, 158, 107733.	4.1	28
25	Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 831-847.	3.3	33
26	Anticonvulsant Activity of Pterostilbene in Zebrafish and Mouse Acute Seizure Tests. Neurochemical Research, 2019, 44, 1043-1055.	3.3	33
27	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT <sub>1A</sub> Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019, 62, 2750-2771.	6.4	21
28	Characterization of the Brain Penetrant Neuropeptide Y Y <sub>2</sub> Receptor Antagonist SF-11. ACS Chemical Neuroscience, 2019, 10, 3454-3463.	3.5	7
29	Influence of the CB <sub>1</sub> cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in mice. Brain Research Bulletin, 2019, 150, 179-185.	3.0	9
30	Agomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A <sub>2A</sub> receptor antagonist, but not DPCPX, a selective adenosine A <sub>1</sub> receptor antagonist. Pharmacological Reports, 2019, 71, 676-681.	3.3	16
31	Effect of Pterostilbene, a Natural Analog of Resveratrol, on the Activity of some Antiepileptic Drugs in the Acute Seizure Tests in Mice. Neurotoxicity Research, 2019, 36, 859-869.	2.7	9
32	Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling. European Journal of Pharmacology, 2019, 865, 172779.	3.5	13
33	Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans. Xenobiotica, 2019, 49, 1209-1220.	1.1	6
34	Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A <sub>2A</sub> Receptor Antagonist. Neurotoxicity Research, 2019, 35, 344-352.	2.7	32
35	Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Current Drug Targets, 2019, 20, 1652-1669.	2.1	10
36	Effect of Tadalafil on Seizure Threshold and Activity of Antiepileptic Drugs in Three Acute Seizure Tests in Mice. Neurotoxicity Research, 2018, 34, 333-346.	2.7	14

#	ARTICLE	IF	CITATIONS
37	The impact of polymers on 3D microstructure and controlled release of sildenafil citrate from hydrophilic matrices. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 119, 234-243.	4.0	5
38	Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018, 146, 381-394.	5.5	37
39	Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel liquid chromatography tandem mass spectrometry analytical method. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 185-196.	3.0	4
40	Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 517-533.	5.5	27
41	The influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1200-1208.	2.4	10
42	DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 1361-1371.	3.0	18
43	Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes. <i>Psychopharmacology</i> , 2018, 235, 2423-2434.	3.1	6
44	Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research. <i>Current Drug Targets</i> , 2018, 20, 122-143.	2.1	23
45	Cytochrome P450 oxidoreductase genetic polymorphism and pantoprazole pharmacokinetics in healthy volunteers. <i>Pomeranian Journal of Life Sciences</i> , 2018, 64, .	0.1	1
46	Increased seizure susceptibility and other toxicity symptoms following acute sulforaphane treatment in mice. <i>Toxicology and Applied Pharmacology</i> , 2017, 326, 43-53.	2.8	36
47	In vitro and in vivo behavior of ground tadalafil hot-melt extrudates: How the carrier material can effectively assure rapid or controlled drug release. <i>International Journal of Pharmaceutics</i> , 2017, 528, 498-510.	5.2	23
48	Effect of sildenafil on the activity of some antidepressant drugs and electroconvulsive shock treatment in the forced swim test in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 339-349.	3.0	8
49	Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. <i>Journal of Neural Transmission</i> , 2017, 124, 387-396.	2.8	8
50	PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 1047-1059.	3.0	13
51	Enantioselective analysis of ibuprofen enantiomers in mice plasma and tissues by high-performance liquid chromatography with fluorescence detection: Application to a pharmacokinetic study. <i>Chirality</i> , 2017, 29, 500-511.	2.6	9
52	Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression. <i>Toxicology and Applied Pharmacology</i> , 2017, 337, 95-103.	2.8	11
53	Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. <i>Neuropharmacology</i> , 2017, 113, 331-342.	4.1	33
54	PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. <i>Current Medicinal Chemistry</i> , 2017, 24, 673-700.	2.4	41

#	ARTICLE	IF	CITATIONS
55	High-Energy Ball Milling as Green Process To Vitrify Tadalafil and Improve Bioavailability. <i>Molecular Pharmaceutics</i> , 2016, 13, 3891-3902.	4.6	42
56	Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice. <i>Pharmacological Reports</i> , 2016, 68, 960-963.	3.3	7
57	Antidepressant-like activity of sildenafil following acute and subchronic treatment in the forced swim test in mice: effects of restraint stress and monoamine depletion. <i>Metabolic Brain Disease</i> , 2016, 31, 1095-1104.	2.9	16
58	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 403-412.	1.6	8
59	Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 211-221.	3.0	46
60	Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. <i>Metabolic Brain Disease</i> , 2016, 31, 803-814.	2.9	21
61	Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice. <i>Pharmacological Reports</i> , 2016, 68, 56-61.	3.3	32
62	Sensitive and precise HPLC method with back-extraction clean-up step for the determination of sildenafil in rat plasma and its application to a pharmacokinetic study. <i>Biomedical Chromatography</i> , 2015, 29, 1559-1566.	1.7	13
63	The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice. <i>Life Sciences</i> , 2015, 136, 13-18.	4.3	15
64	Activity and Safety of Inhaled Itraconazole Nanosuspension in a Model Pulmonary <i>Aspergillus fumigatus</i> Infection in Inoculated Young Quails. <i>Mycopathologia</i> , 2015, 180, 35-42.	3.1	22
65	Pharmacokinetics and tissue distribution of the new non-imidazole histamine H3 receptor antagonist 1-[3-(4-tert-butylphenoxy) propyl]piperidine in rats. <i>Xenobiotica</i> , 2015, 45, 912-920.	1.1	3
66	Synthesis of 8-alkoxy-1,3-dimethyl-2, 6-dioxopurin-7-yl-substituted acetohydrazides and butanehydrazides as analgesic and anti-inflammatory agents. <i>Heterocyclic Communications</i> , 2015, 21, 273-278.	1.2	7
67	Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 122, 173-181.	2.9	55
68	Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. <i>Experimental Gerontology</i> , 2014, 57, 107-113.	2.8	15
69	Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 83, 44-53.	4.3	46
70	A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail ( <i>Coturnix</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 suspension. <i>Medical Mycology</i> , 2013, 51, 800-810.	0.7	12
71	Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice. <i>Pharmacological Reports</i> , 2012, 64, 1259-1266.	3.3	13
72	Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 121-126.	4.8	12

#	ARTICLE	IF	CITATIONS
73	Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 103, 273-278.	2.9	15
74	CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1267-1274.	1.9	50
75	Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice. <i>Journal of Neural Transmission</i> , 2012, 119, 645-652.	2.8	16
76	Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2010, 33, 135-141.	0.7	29
77	Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 495-501.	2.4	6
78	Pharmacokinetic-Pharmacodynamic Modeling of Methylxanthine Derivatives in Mice Challenged with High-Dose Lipopolysaccharide. <i>Pharmacology</i> , 2010, 85, 264-271.	2.2	18
79	Pharmacokinetic Interaction Between Verapamil and Methylxanthine Derivatives in Mice. <i>Drug Metabolism Letters</i> , 2010, 4, 15-24.	0.8	3
80	Pretreatment with R(+)-verapamil significantly reduces mortality and cytokine expression in murine model of septic shock. <i>International Immunopharmacology</i> , 2009, 9, 478-490.	3.8	18
81	Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 377, 637-645.	3.0	29
82	Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis. <i>Paediatric Anaesthesia</i> , 2007, 17, 637-646.	1.1	11
83	Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. <i>Paediatric Anaesthesia</i> , 2006, 16, 761-768.	1.1	16
84	Interconversion and tissue distribution of pentoxifylline and lisofylline in mice. <i>Chirality</i> , 2006, 18, 644-651.	2.6	15
85	Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. <i>Pharmacological Reports</i> , 2006, 58, 746-52.	3.3	45
86	Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 524-529.	2.9	39
87	Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1438-1454.	3.3	4
88	Diversity of Mechanism-Based Pharmacodynamic Models. <i>Drug Metabolism and Disposition</i> , 2003, 31, 510-518.	3.3	318
89	Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. <i>Psychopharmacology</i> , 2001, 154, 38-42.	3.1	36
90	Approaches to pharmacokinetic/pharmacodynamic modeling during pregnancy. <i>Seminars in Perinatology</i> , 2001, 25, 124-132.	2.5	8